Economic evaluations.
Anthonisen
Nick R
NR
D000420:Albuterol / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D000730:Androstadienes / Q000191:economics / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D019819:Budesonide / Q000191:economics / Q000627:therapeutic use; D002170:Canada; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000191:economics / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D000068298:Fluticasone; D000068759:Formoterol Fumarate; D006760:Hospitalization / Q000191:economics; D006801:Humans; D010366:Peak Expiratory Flow Rate; D000068299:Salmeterol Xinafoate; D013183:Sputum / Q000166:cytology
D000730:Androstadienes; D001993:Bronchodilator Agents; D004983:Ethanolamines; D019819:Budesonide; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol; D000068759:Formoterol Fumarate